Pharmaceutical

Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers

Rgenta has secured approval for its IND application for RGT-61159, an oral small molecule RNA modulator, to treat cancers.

Jul 12, 2024 - 04:00
Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers
Rgenta has secured approval for its IND application for RGT-61159, an oral small molecule RNA modulator, to treat cancers.
Read the original article

Tags:

Previous Article

Hong Kong approves Leqembi for Alzheimer’s treatment

Next Article

HarvestHub app tackles supply chain, food insecurity issues

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry

Opinion: Pumping milk at JPM was a nightmare. It’s part...

Jan 12, 2024

Bupa is leveraging its unique position to develop IoT and AI features

Bupa is leveraging its unique position to develop IoT a...

Jan 17, 2024

How a supplement company became a haven for health misinformation

How a supplement company became a haven for health misi...

Sep 8, 2023